Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: Implications in the cellular response to Ara-C

Biochemical Journal

Volumn 387, Issue 1, 2005, Pages 231-238

  Sánchez Arévalo Lobo, Victor Javier ^a   Aceves Luquero, Clara Isabel ^b   Álvarez Vallina, Luis ^a   Tipping, Alex J ^c   Viniegra, Juan Guinea ^b   Hernández Losa, Javier ^d   Parada Cobo, Carlos ^d   Galán Moya, Eva María ^b   Gayoso Cruz, Jorge ^a   Melo, Junia V ^c   Ramón Y Cajal, Santiago ^d   Sánchez Prieto, Ricardo ^b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Universidad de Castilla La Mancha   (Spain)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

1 D arabinofuranosylcytosine (Ara C); Bcr Abl protein; Leukaemia; P38 MAPK (mitogen activated protein kinase); Phosphorylation

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; CELLS; DISEASE CONTROL; GROWTH KINETICS; SUBSTRATES;

BIOLOGICAL SUBSTRATES; CHRONIC MYELOID LEUKAEMIA; MITOGEN ACTIVATED PROTEIN KINASE; SIGNALLING PATHWAYS;

ENZYMES;

6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ABELSON KINASE; BCR ABL PROTEIN; CHIMERIC PROTEIN; CYTARABINE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN P73; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CELL STRAIN; CELL STRAIN 293T; CELL STRAIN BAF 3; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SUBSTRATE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

CELL LINE; CELL LINE, TUMOR; CYTARABINE; DNA-BINDING PROTEINS; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; GENES, TUMOR SUPPRESSOR; HUMANS; KIDNEY; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; TUMOR SUPPRESSOR PROTEINS; U937 CELLS;

EID: 20244370529     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20040927     Document Type: Article

References (43)

1. Deininger, M. W., Goldman, J. M. and Melo, J. V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356
2. Danial, N. N. and Rothman, P. (2000) JAK-STAT signaling activated by Abl oncogenes. Oncogene 19, 2523-2531
3. Raitano, A. B., Halpern, J. R., Hambuch, T. M. and Sawyers, C. L. (1995) The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. U.S.A. 92, 11746-11750
4. Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O. et al. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16, 6151-6161
5. Mayer, I. A., Verma, A., Grumbach, I. M., Uddin, S., Lekmine, F., Ravandi, F., Majchrzak, B., Fujita, S., Fish, E. N. and Platanias, L. C. (2001) The p38 MAPK pathway mediates the growth inhibitory effects of interferon-α in BCR-ABL-expressing cells. J. Biol. Chem. 276, 28570-28577
6. Nebreda, A. R. and Porras, A. (2000) p38 MAP kinases: beyond the stress response. Trends Biochem. Sci. 25, 257-260
7. Ambrosino, C. and Nebreda, A. R. (2001) Cell cycle regulation by p38 MAP kinases. Biol. Cell. 93, 47-51
8. Martin-Blanco, E. (2000) p38 MAPK signalling cascades: ancient roles and new functions. BioEssays 22, 637-645
9. Ono, K. and Han, J. (2000) The p38 signal transduction pathway: activation and function. Cell Signal. 12, 1-13
10. Sanchez-Prieto, R., Rojas, J. M., Taya, Y. and Gutkind, J. S. (2000) A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation ot p53 on genotoxic stress by chemotherapeutic agents. Cancer Res. 60, 2464-2472
11. Bulavin, D. V., Demidov, O. N., Saito, S., Kauraniemi, P., Phillips, C., Amundson, S. A., Ambrosino, C., Sauter, G., Nebreda, A. R., Anderson, C. W. et al. (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 20, 210-215
12. Kharbanda, S., Yuan, Z. M., Weichselbaum, R. and Kufe, D. (1998) Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 17, 3309-3318
13. Pandey, P., Raingeaud, J., Kaneki, M., Weichselbaum, R., Davis, R. J., Kufe, D. and Kharbanda, S. (1996) Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms. J. Biol. Chem. 271, 23775-23779
14. Saleem, A., Datta, R., Yuan, Z. M., Kharbanda, S. and Kufe, D. (1995) Involvement of stress-activated protein kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Cell. Growth. Differ. 6, 1651-1658
15. Stadheim, T. A., Saluta, G. R. and Kucera, G. L. (2000) Role of c-Jun N-terminal kinase/p38 stress signaling in 1-beta-D-arabinofuranosylcytosine- induced apoptosis. Biochem. Pharmacol. 59, 407-418
16. Huang, Y., Yuan, Z. M., Ishiko, T., Nakada, S., Utsugisawa, T., Kato, T., Kharbanda, S. and Kufe, D. W. (1997) Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine. Oncogene 15, 1947-1952
17. Sanchez-Prieto, R., Sanchez-Arevalo, V. J., Servitja, J. M. and Gutkind, J. S. (2002) Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 21, 974-979
18. Agami, R., Blandino, G., Oren, M. and Shaul, Y. (1999) Interaction ot c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (London) 399, 809-813
19. Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, Jr, W. G., Levrero, M. and Wang, J. Y. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (London) 399, 806-809
20. Yuan, Z. M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y. Y., Lu, H., Kharbanda, S., Weichselbaum, R. and Kufe, D. (1999) p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (London) 399, 814-817
21. Cong, F. and Goff, S. P. (1999) c-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation. Proc. Natl. Acad. Sci. U.S.A. 96, 13819-13824
22. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B. J. and Lydon, N. B. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104
23. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J. and Lydon, N. B. (1996) Effects of a selective inhibitor ot the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566
24. Deininger, M. W., Goldman, J. M., Lydon, N. and Melo, J. V. (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90, 3691-3698
25. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. and Nunez, G. (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687-689
26. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R. and Landvatter, S. W. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (London) 372, 739-746
27. Losa, J. H., Cobo, C. P., Viniegra, J. G., Sanchez-Arevalo Lobo, V. J., Ramon y Cajal, S. and Sanchez-Prieto, R. (2003) Role of the p38 MARK pathway in cisplatin-based therapy. Oncogene 22, 3998-4006
28. Raina, D., Mishra, N., Kumar, S., Kharbanda, S., Saxena, S. and Kufe, D. (2002) Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D- arabinoluranosylcytosine. Mol. Pharmacol. 61, 1489-1495
29. Cortez, D., Reuther, G. and Pendergast, A. M. (1997) The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15, 2333-2342
30. Korus, M., Mahon, G. M., Cheng, L. and Whitehead, I. P. (2002) p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene 21, 4601-4612
31. Neshat, M. S., Raitano, A. B., Wang, H. G., Reed, J. C. and Sawyers, C. L. (2000) The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol. Cell. Biol. 20, 1179-1186
32. Alvarado-Kristensson, M., Porn-Ares, M. I., Grethe, S., Smith, D., Zheng, L. and Andersson, T. (2002) p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase activities have opposite effects on human neutrophil apoptosis. FASEB J. 16, 129-131
33. Dong, C., Davis, R. J. and Flavell, R. A. (2002) MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55-72
34. 2-terminal kinase in transformed B lymphoblasts. Nat. Genet. 32, 201-205
35. Ashcroft, M. and Vousden, K. H. (1999) Regulation of p53 stability. Oncogene 18, 7637-7643
36. Colman, M. S., Afshari, C. A. and Barrett, J. C. (2000) Regulation of p53 stability and activity in response to genotoxic stress. Mutat. Res. 462, 179-188
37. Lohrum, M. A. and Vousden, K. H. (1999) Regulation and activation of p53 and its family members. Cell. Death. Differ. 6, 1162-1168
38. Blagosklonny, M. V. (1997) Loss of function and p53 protein stabilization. Oncogene 15, 1889-1893
39. Thiesing, J. T., Ohno-Jones, S., Kolibaba, K. S. and Druker, B. J. (2000) Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96, 3195-3199
40. Yu, C., Krystal, G., Varticovksi, L., McKinstry, R., Rahmani, M., Dent, P. and Grant, S. (2002) Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer. Res. 62, 188-199
41. Klejman, A., Rushen, L., Morrione, A., Slupianek, A. and Skorski, T. (2002) Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21, 5868-5876
42. Wong, S., McLaughlin, J., Cheng, D. and Witte, O. N. (2003) Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood 101, 4088-4097
43. Khaled, A. R., Moor, A. N., Li, A., Kim, K., Ferris, D. K., Muegge, K., Fisher, R. J., Fliegel, L. and Durum, S. K. (2001) Trophic factor withdrawal: p38 mitogen-activated protein kinase activates NHE1, which induces intracellular alkalinization. Mol. Cell. Biol. 21, 7545-7557